ArticleFrontiers in endocrinology2025
Microwave ablation vs. surgery for T1bN0M0 papillary thyroid carcinoma: a propensity score-matched cohort study.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To assess the efficacy and safety of microwave ablation (MWA) in treating T1bN0M0 (T1b) papillary thyroid carcinoma (PTC) by comparing patient outcomes with those following surgical resection in treating T1b PTC. Methods: In this retrospective analytical study, patients who were diagnosed with T1b PTC in the ultrasound department of our hospital between April 2019 and October 2023. The patients were divided into MWA group and surgery group according to the different treatment methods. A 1:1 propensity score matching (PSM) analysis was performed to compare local tumor progression (LTP), relapse-free survival (RFS), and complication rates between patients treated with MWA and surgical resection. Results: After 1:1 PSM accounting for sex, age, nodule location, position and follow-up time as potential confounders, 172 patients with T1b disease were matched with 1:1 PSM, 86 patients each in the surgery and MWA treatment groups. Following PSM, there was no statistically significant difference in LTP (2.33% vs. 3.49%, p = 0.650) between the MWA group and the surgical group. The volume reduction rate (VRR) was 98.53 ± 6.50%. No permanent complications were observed after MWA, and no cases of distant metastasis or delayed surgery occurred. Conclusions: MWA could serve as a reasonable alternative besides surgery for T1b patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.